Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
topic_facet:"Recruitment Status: Active, not recruiting"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Active%2C+not+recruiting%22&lookfor=%22Myeloma%22&type=Subject
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Active%2C+not+recruiting%22&lookfor=%22Myeloma%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Active%2C+not+recruiting%22&lookfor=%22Myeloma%22&type=Subject
PubPharm (471)
1
Agriculture Health Study : The Main Agricultural Health Study - A Prospective Study of Cancer and Other Diseases Among Men and Women in Agriculture
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) : Molecular Analysis for Therapy Choice (MATCH)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
3
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) : An Open-Label, Multicenter Phase 1b Study Investigating the Safety of TAK-079 in Combination With Backbone Regimens for the Treatment of Patients With Newly Diagnosed Multiple Myeloma and for Whom Stem Cell Transplantation Is Not Planned as Initial Therapy
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
4
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb : MAGNETISMM-3 AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 2 STUDY OF ELRANATAMAB (PF-06863135) MONOTHERAPY IN PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
5
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) : MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients With Tumors Wtih mTOR Mutations
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
6
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) : MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (Tak-228) in Patients With Tumors With TSC1 or TSC2 Mutations
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
7
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) : MATCH Treatment Subprotocol Z1E: Larotrectinib (LOXO-101) in Patients With Tumors With NTRK Fusions
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
8
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) : MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients With Tumors With cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuorendocrine Tumor)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
9
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma : Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
10
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma : A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[48]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Recruitment Status: Active, not recruiting
Medienart
471
Aufsätze
471
E-Artikel
471
E-Ressourcen
Zeitschriftentitel
445
ClinicalTrials.gov
26
WHO International Clinical Trials Registry Plat...
Thema
471
610
Recruitment Status: Active, not recruiting
443
Multiple Myeloma
441
Study Type: Interventional
362
Neoplasms, Plasma Cell
181
Phase: Phase 2
89
Phase: Phase 1
77
Phase: Phase 3
65
Lymphoma
55
Phase: Phase 1, Phase 2
49
Neoplasms
30
Smoldering Multiple Myeloma
30
Study Type: Observational
28
Medical Condition: Multiple Myeloma
21
Leukemia
19
Myelodysplastic Syndromes
16
Leukemia, Lymphocytic, Chronic, B-Cell
14
Hematologic Neoplasms
14
Leukemia, Myeloid
12
Leukemia, Myeloid, Acute
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
463
2020-
8
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
471
Englisch
Haven't found what you're looking for?
Wird geladen...